Misoprostol and the debate over off-label drug use.

  title={Misoprostol and the debate over off-label drug use.},
  author={Andrew D Weeks and Christian Fiala and Peter J Safar},
  journal={BJOG : an international journal of obstetrics and gynaecology},
  volume={112 3},
Many readers will be surprised to learn that antenatal betamethasone is not licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA, formally the Medicines Control Agency) to prevent neonatal respiratory distress syndrome in pregnancy. Nor is oxytocin 10 units im licensed to prevent postpartum haemorrhage. However, oxytocin 5 units iv is licensed to treat a missed miscarriage and norethisterone (days 19–26) is licensed to treat menorrhagia despite now being considered… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 22 extracted citations


Publications referenced by this paper.
Showing 1-10 of 11 references

Managing Complications in Pregnancy and Childbirth

  • M Mathai, H Sanghvi, RJ. Guidotti
  • Geneva: World Health Organisation,
  • 2000

Similar Papers

Loading similar papers…